In oral solid-dose production for companion animals and food-producing species, granulated veterinary API is first screened through a 500 µm safety sieve before low-shear blending. The fraction above 850 µm is normally reserved for large bolus tooling, while the fraction below 75 µm is held under 20% w/w to avoid segregation across the force feeder. Blending is performed in a double-cone or V-blender at 10–15 rpm for 15–20 min, with external disintegrant added only after the granule has reached a uniformity endpoint. Tablet compression is carried out on a rotary press with force feeder, precompression roll set at 2–4 kN and main compression at 8–12 kN for flat-faced bevel-edge tooling in the 10–12 mm diameter range. Crushing strength is measured according to Ph. Eur. 2.9.8; small companion-animal tablets commonly fall between 40 N and 80 N, while dense bovine boluses may require 150–250 N depending on the bolus geometry. Uniformity of dosage units is evaluated by Ph. Eur. 2.9.40 or USP <905>; an acceptance value not more than 15.0 is a standard release target. Disintegration is measured in water at 37 °C per Ph. Eur. 2.9.1; uncoated tablets are expected to disintegrate within 15 min unless a veterinary monograph specifically permits 30 min for dense or sustained-release bolus formats. The dominant process risk is over-lubrication: magnesium stearate above 1% w/w can produce a hydrophobic film that delays disintegration without improving ejection force. If the incoming granule is already a wet-granulated intermediate, re-granulation is avoided because it shifts particle size distribution and increases fine generation during downstream compression.

Does the same granule fill hard gelatin capsules without destructive over-compression?

Hard gelatin capsule filling introduces a different set of constraints than tablet compression. The granule must flow into dosator or tamping-pin stations without bridging; powder flow is evaluated by Ph. Eur. 2.9.36, and Carr index derived from Ph. Eur. 2.9.34 below 20 is generally required for consistent fill weight. Granule moisture above 2.0% is a known failure mode because moisture migration from the granule can embrittle gelatin shells stored at 25 °C and 60% RH. Fill weight uniformity is checked by Ph. Eur. 2.9.5 or USP <905>; for veterinary capsule strengths below 100 mg fill weight, relative standard deviation is normally controlled under 2.0% at machine validation. Dissolution is tested with Ph. Eur. 2.9.3 Apparatus II at 50 rpm; granule-derived capsules must release the active ingredient in 0.1 M HCl or buffer as specified by the registered monograph. The critical threshold is lubricant concentration: more than 1% w/w magnesium stearate can extend disintegration beyond 30 min because the hydrophobic layer prevents liquid penetration into the granule pores. Pre-blend shear is kept lower than in tablet production because capsule formulations do not require the same compactibility, and excessive fines below 75 µm can cause static adhesion to gelatin walls and dusting around the encapsulation line.

Sterile injectable manufacture from a granule-form veterinary API is limited to molecules that dissolve completely in an aqueous or non-aqueous vehicle and do not carry tablet-grade binders or water-insoluble filler residues into the final solution. The granule is charged into a depyrogenated mixing vessel containing Water for Injections at 20–25 °C; dissolution is continued under low-shear agitation until visual clarity is achieved. The resulting solution is prefiltered through a 0.45 µm cartridge and then sterile-filtered through a 0.22 µm PVDF or PES membrane before aseptic filling. Filling is conducted in a Grade A environment supported by ISO 14644-1 Class 5 background; unidirectional airflow velocity is maintained at 0.45 m/s ± 20% according to EU GMP Annex 1. Endotoxin is controlled by Ph. Eur. 2.6.14; no single endotoxin limit applies across all veterinary injectables, and for many intravenous products a conservative design target of 0.5 EU/mg is used only when the registered specification allows it. Terminal sterilisation at 121 °C for 15 min is preferred for heat-stable molecules, while heat-labile APIs require aseptic filtration and cannot be terminally sterilised. If the granule contains povidone, starch, or lactose that is not documented in the injectable dossier, reprocessing into injectable-grade material is not permitted because compendial injectable formulations require each excipient to appear in the approved composition. Published stability data for every species-specific injectable configuration are limited, and the registered formulation rather than a generic granule specification determines the maximum hold time between dissolution and sterile filtration.

When the granule is dispersed into drinking water systems at farm level

Drinking water and oral powder applications require the granule to dissolve rapidly in cold water and remain stable in stock solutions under variable farm conditions. A proportioner pump set at 1:100 draws 0.1 L of stock solution into 10 L of line flow per minute; this dilution factor is calibrated against actual water flow with a graduated cylinder before each treatment cycle. The stock solution is commonly prepared at 100 g/L, but solubility boundaries differ by molecular form; published data for this specific configuration is limited. Hard water above 250 mg/L CaCO₃ equivalent can reduce solubility of acid-salt APIs, so a chelating agent such as EDTA may be included at 0.1–0.5% w/w only if compatibility is demonstrated in the formulation dossier. Water pH above 8.0 accelerates degradation of base-labile actives; buffered formulations use citrate or phosphate systems to maintain pH 5.5–6.5 in the final diluted solution. In-use stability after dilution is limited to 24 h unless preservative efficacy has been demonstrated by Ph. Eur. 5.1.3. Light-exposed stock tanks on farm require opaque or UV-protected construction; oxidation-sensitive molecules are typically packaged as single-dose sachets to avoid repeated opening of bulk containers. A separate process failure mode is nozzle clogging from undissolved fine particles below 75 µm aggregating in hard water, which is controlled by pre-dissolving in a separate mixer and passing the stock solution through a 20 µm in-line filter before the proportioner.

Feed-mill premix production from granulated veterinary API is regulated by FDA 21 CFR 225 and European medicated feed legislation rather than by human pharmaceutical tablet standards. The granule is first pre-blended with a carrier such as limestone flour or corn cob at a ratio between 1:10 and 1:25, then added to a horizontal ribbon mixer operating at 20–30 rpm for 10–15 min. Mix homogeneity is assessed by active assay at 10 sampling points; a coefficient of variation below 5% is a typical release acceptance for medicated feed. The critical operational boundary is carryover: the number of flush batches required after a medicated run is derived from worst-case tracer studies on the specific mixer, and no fixed single value is valid across all equipment. A risk-based initial threshold of 1% of the lowest therapeutic dose is sometimes used to design cleaning validation, but the registered feed safety limit and species-specific maximum residue limits govern the final release decision. Powder flow is evaluated by Ph. Eur. 2.9.36; granules with Carr index above 20 derived from Ph. Eur. 2.9.34 tend to segregate in the mixer and produce high assay variability. Thermal lability is a further constraint when the premix is subsequently pelleted at temperatures above 70 °C; heat-stable actives are preferred for pelleted feeds, while heat-labile actives are restricted to meal or top-dress applications. Table 2 summarises the regulatory and analytical controls for granule-derived premix.

Oral drench solutions and pump calibration limits

Oral drench production requires the granule to dissolve in a vehicle with viscosity suitable for repeat-dose drench guns; target viscosity is generally below 50 mPa·s at 20 °C because higher values cause nozzle cavitation and variable delivered volume. Viscosity is measured by Ph. Eur. 2.2.8 after complete dissolution and temperature equilibration. Drench gun output is verified before each herd or flock treatment using a graduated cylinder; acceptable variation between consecutive doses is ±5%. The formulation is often prepared at 10 mg/mL or 100 mg/mL depending on the species and dosing schedule; this is a product-specific parameter and published data for every species is limited. In-use stability after dilution in warm water is limited to 24 h unless a preservative efficacy test has been completed according to Ph. Eur. 5.1.3. Residual particles above 50 µm are removed by in-line filtration to prevent blockage of the drench nozzle; the filter is matched to the gun orifice diameter, typically 0.4–0.8 mm in small-ruminant equipment. Viscosity drift after pH adjustment is a separate batch-release failure mode: acid-base neutralisation can build ionic strength and thicken the solution after 6–8 h, so viscosity is measured again at the end of the holding time rather than only immediately after compounding.

Topical solutions demand full dissolution before skin-contact pH is adjusted

Topical spray, auricular, and teat dip solutions are formulated from water-soluble veterinary granules only after complete dissolution in demineralised water; residual undissolved particles above 50 µm are removed by filtration through a 20 µm in-line cartridge to prevent nozzle clogging. pH is adjusted after dissolution to a skin-compatible range of 4.0–6.5; values outside this range may increase dermal irritation or alter the partition coefficient of the active at the stratum corneum interface. Viscosity is kept below 10 mPa·s at 20 °C for spray equipment; teat dip formulations may be thickened only after the active has fully dissolved, because adding polymer before dissolution can encapsulate undissolved granule fragments and produce non-uniform active delivery. Microbial quality is controlled by Ph. Eur. 5.1.3; non-sterile topical solutions require a preservative efficacy test and a total aerobic microbial count specification fixed in the registration dossier. The granule-derived excipients must be documented as safe for skin contact; tablet-grade magnesium stearate or starch residues are not automatically acceptable in topical formulations without supporting safety data. Light-sensitive actives are filled into amber or opaque containers, and oxidation-sensitive solutions are blanketed with nitrogen during filling to keep dissolved oxygen below 0.5 ppm where the stability data require it.